Carboplatin is a new cisplatin analogue that has a spectrum of activity similar to that of the parent compound. Since the dose intensity of cisplatin is important in achieving optimal results, it is probable that carboplatin dosage is an important factor in maximizing efficacy, particularly in platinum-sensitive tumors. Renal function and prior history of chemotherapy are the most important factors in selecting an individual patient's dose. In ovarian cancer patients, the usual dose of carboplatin will be 300 to 400 mg/m2 and will depend upon whether carboplatin is used as salvage therapy or as part of an induction combination chemotherapy regimen in previously untreated patients.